Browsing Tag
NASDAQ
805 posts
Can Supermicro justify a $7bn financing plan as SMCI investors weigh AI order demand and dilution risk?
Find out why Supermicro’s $7bn financing plan could reshape SMCI stock sentiment, AI server demand, and dilution risk.
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Why XCF Global’s 180-day Nasdaq extension may not be enough for SAFX bulls
XCF Global keeps its Nasdaq listing with a 180-day extension, but SAFX still faces bid-price pressure. Read what the reprieve means now.
Could Applied Materials’ Singapore expansion strengthen AMAT stock’s AI chip supply-chain story?
Find out how Applied Materials’ Singapore expansion could strengthen AMAT stock sentiment and the AI chip supply-chain story.
GSK Nuvalent acquisition puts $GSK in focus as $10.6bn oncology bet reshapes lung cancer pipeline
GSK is buying Nuvalent for USD 10.6bn to expand in lung cancer. Find out what the $GSK oncology deal means for investors.
Aldeyra Therapeutics brings biotech CFO experience to board amid ALDX regulatory reset
Find out how Aldeyra Therapeutics’ new board appointment could shape ALDX stock sentiment, FDA strategy and reproxalap’s next chapter for investors now.
Could CME Group’s Bitcoin Volatility futures deepen institutional crypto risk management?
Find out how CME Group’s Bitcoin Volatility futures could reshape institutional crypto risk management and CME stock sentiment.
Can Hut 8’s $4.25bn data center financing turn AI infrastructure into a bigger HUT stock catalyst?
Find out how Hut 8’s $4.25bn Beacon Point financing could reshape HUT stock sentiment and its AI data center growth strategy.
Could Cognizant’s sovereign physical AI platform become a major enterprise automation catalyst?
Find out how Cognizant’s sovereign physical AI platform could reshape CTSH stock sentiment and enterprise automation strategy.
Corcept Therapeutics (CORT) CATALYST data puts Korlym at centre of difficult-to-control diabetes strategy
Find out how Corcept Therapeutics’ ADA data could reshape cortisol screening in hard-to-control diabetes and GLP-1 care.